Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 336

1.

Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.

Sevigny JJ, Ryan JM, van Dyck CH, Peng Y, Lines CR, Nessly ML; MK-677 Protocol 30 Study Group.

Neurology. 2008 Nov 18;71(21):1702-8. doi: 10.1212/01.wnl.0000335163.88054.e7.

PMID:
19015485
2.

Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD.

Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Petanceska S, Browne P, Wassar D, Johnson-Traver S, Lochhead J, Ziolkowski C.

Curr Alzheimer Res. 2005 Jul;2(3):343-53.

PMID:
15974900
5.

Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.

Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT; Memantine MEM-MD-12 Study Group.

Curr Alzheimer Res. 2008 Feb;5(1):83-9.

PMID:
18288936
6.

Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.

Wilkinson D, Andersen HF.

Dement Geriatr Cogn Disord. 2007;24(2):138-45. Epub 2007 Jul 4.

PMID:
17622761
7.

A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population.

Suh GH, Yeon Jung H, Uk Lee C, Hoon Oh B, Nam Bae J, Jung HY, Ju YS, Kil Yeon B, Park J, Hong I, Choi S, Ho Lee J; Korean Galantamine Study Group.

Clin Ther. 2004 Oct;26(10):1608-18.

PMID:
15598477
8.

Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study.

Reines SA, Block GA, Morris JC, Liu G, Nessly ML, Lines CR, Norman BA, Baranak CC; Rofecoxib Protocol 091 Study Group.

Neurology. 2004 Jan 13;62(1):66-71.

PMID:
14718699
9.

The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture.

Bach MA, Rockwood K, Zetterberg C, Thamsborg G, H├ębert R, Devogelaer JP, Christiansen JS, Rizzoli R, Ochsner JL, Beisaw N, Gluck O, Yu L, Schwab T, Farrington J, Taylor AM, Ng J, Fuh V; MK 0677 Hip Fracture Study Group.

J Am Geriatr Soc. 2004 Apr;52(4):516-23.

PMID:
15066065
10.

Donepezil preserves cognition and global function in patients with severe Alzheimer disease.

Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, Sun Y, Perdomo CA, Richardson S.

Neurology. 2007 Jul 31;69(5):459-69.

PMID:
17664405
11.

Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.

Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, McDonald S.

Am J Geriatr Psychiatry. 2006 Aug;14(8):704-15.

PMID:
16861375
12.

The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics.

Jones RW, Kivipelto M, Feldman H, Sparks L, Doody R, Waters DD, Hey-Hadavi J, Breazna A, Schindler RJ, Ramos H; LEADe investigators.

Alzheimers Dement. 2008 Mar;4(2):145-53. doi: 10.1016/j.jalz.2008.02.001.

PMID:
18631958
13.

A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease.

Pasqualetti P, Bonomini C, Dal Forno G, Paulon L, Sinforiani E, Marra C, Zanetti O, Rossini PM.

Aging Clin Exp Res. 2009 Apr;21(2):102-10.

PMID:
19448381
14.

A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease.

Thal LJ, Ferguson JM, Mintzer J, Raskin A, Targum SD.

Neurology. 1999 Apr 12;52(6):1146-52.

PMID:
10214735
15.

Metrifonate treatment of AD: influence of APOE genotype.

Farlow MR, Cyrus PA, Nadel A, Lahiri DK, Brashear A, Gulanski B.

Neurology. 1999 Dec 10;53(9):2010-6.

PMID:
10599773
16.

Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.

Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, Shannon HE, Tollefson GD, Rasmussen K, Bymaster FP, Hurley DJ, Potter WZ, Paul SM.

Arch Neurol. 1997 Apr;54(4):465-73.

PMID:
9109749
17.

Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results.

Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Browne P, Wasser D, Johnson-Traver S, Lochhead J, Ziolwolski C.

Arch Neurol. 2005 May;62(5):753-7.

PMID:
15883262
18.

Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial.

Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi AH, Khani M.

J Clin Pharm Ther. 2003 Feb;28(1):53-9.

PMID:
12605619
19.

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C.

Neurology. 2000 Jun 27;54(12):2269-76.

PMID:
10881251
20.

Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.

Mohs RC, Shiovitz TM, Tariot PN, Porsteinsson AP, Baker KD, Feldman PD.

Am J Geriatr Psychiatry. 2009 Sep;17(9):752-9. doi: 10.1097/JGP.0b013e3181aad585.

PMID:
19700948

Supplemental Content

Support Center